S-1/A: GlucoTrack Files Amendment No. 4 to Form S-1 Registration Statement
S-1/A (Registration Statement Amendment)
GlucoTrack, Inc. files an amendment to its Form S-1 registration statement, primarily to include an updated legal opinion regarding the shares, warrants, and related securities being offered.
Summary
- GlucoTrack, Inc. has filed Amendment No. 4 to its Registration Statement on Form S-1.
- The amendment primarily includes the filing of Exhibit 5.1, which is an opinion from Nelson Mullins Riley & Scarborough LLP.
- The prospectus remains unchanged.
- The registration statement covers the offering of 7,462,686 shares of common stock, pre-funded warrants to purchase common stock, Series A common warrants, and Series B common warrants.
- The maximum aggregate offering price for these securities is $10,000,000.
- The document details other expenses of issuance and distribution, including SEC registration fees ($147.60), FINRA filing fees ($1,500.00), printing and mailing ($25,000.00), accounting fees ($40,000.00), legal fees ($90,000.00), and miscellaneous fees ($7,500.00), totaling $164,147.60.
- The document also outlines indemnification of directors and officers, recent sales of unregistered securities, and a list of exhibits.
Sentiment
Score: 6
Explanation: The document is a regulatory filing, so the sentiment is neutral. It provides necessary information for investors but doesn't express optimism or pessimism.
Future Outlook
The document does not contain specific forward-looking statements beyond the offering itself.
Industry Context
This filing is a standard step for companies seeking to raise capital through public markets, particularly in the biotechnology or medical device sectors.
Related Party Transactions
- The company entered into an Intellectual Property Purchase Agreement with Paul Goode, the company's CEO, issuing shares based on performance milestones.
Stakeholder Impact
- Shareholders will be affected by the potential dilution from the issuance of new shares and warrants.
- The capital raise could provide the company with funds to further develop its technology and expand its business.
Next Steps
- The company will proceed with the offering of securities as described in the registration statement.
- The company will file further amendments as necessary.
Key Dates
| Date | Description |
|---|---|
| October 7, 2022 | Company entered into Intellectual Property Purchase Agreement with Paul Goode. |
| December 29, 2023 | 20,000 shares of Common Stock were earned under the terms of the IP Purchase Agreement. |
| February 6, 2024 | 20,000 shares of Common Stock were issued to Seller. |
| February 13, 2024 | Company entered into an Exchange Agreement with certain shareholders. |
| February 13, 2024 | Company closed the Exchange and issued 3,593,203 shares of Common Stock. |
| April 22, 2024 | Company entered into a private placement agreement. |
| May 17, 2024 | Certificate of Amendment to Amended and Restated Certificate of Incorporation was filed. |
| June 14, 2024 | First Amendment to Bylaws dated. |
| July 1, 2024 | Company entered into note and warrant purchase agreements with certain officers, directors, and existing investors. |
| July 1, 2024 | Closing of the private placement occurred. |
| July 18, 2024 | Company entered into a series of convertible promissory notes with certain investors. |
| July 30, 2024 | Company entered into a convertible promissory note and three warrant agreements with an investor. |
| August 23, 2024 | Two of the July 1 Investors entered into conversion agreements with the Company. |
| September 5, 2024 | Another July 1 Investor entered into a Conversion Agreement with the Company. |
| September 16, 2024 | Registration Statement on Form S-1 initially filed with the SEC. |
| November 8, 2024 | Amendment No. 4 to Form S-1 filed. |
Keywords
Registration Statement, Form S-1, Amendment, Common Stock, Warrants, Offering, Securities, Private Placement, GlucoTrack, Indemnification
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.